Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Elizabeth Sachs, MS
- Phone Number: 9196609849
- Email: elizabeth.sachs@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University
-
Contact:
- Elizabeth Sachs
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
• Has undergone or is scheduled for proximal femur replacement by an Ortho Oncology surgeon
Exclusion Criteria:
- Non-ambulatory before or after the procedure
- Subjects who, in the opinion of the investigator, have not or likely will not complete at least some portion of the investigator's recommended follow-up
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Proximal Femur Replacement
The proximal femur is a common site for primary bone sarcomas and metastatic disease.
The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
|
The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Musculoskeletal Tumor Society (MSTS) score
Time Frame: up to 24 months postoperatively
|
The Musculoskeletal Tumor Society (MSTS) score of extremity function.
The total score ranges from 0 to 30, with higher scores indicating better function.
|
up to 24 months postoperatively
|
|
Harris Hip Score
Time Frame: up to 24 months postoperatively
|
The Harris Hip Score (HHS) is a clinician-based outcome measure that is frequently used for the evaluation of patients following a Total Hip Arthroplasty (THA).
The survey has ten questions and scores ranging from 0-100, with higher scores representing less dysfunction and better outcomes.
|
up to 24 months postoperatively
|
|
Number of patients with an implant-related complication as reported on the adverse event form upon participation completion.
Time Frame: up to 24 months postoperatively
|
The adverse event form records the occurence of implant-related complications that occur during study participation.
|
up to 24 months postoperatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gait Analysis as reported on the study's case report form
Time Frame: up to 24 months postoperatively
|
Motion data collected from gait analysis testing will be evaluated with OpenCap.
|
up to 24 months postoperatively
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: William Eward, MD, DVM, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Pro00082717
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
NCT06820957Active, not recruitingMetastatic Ewing Sarcoma | CIC-Rearranged Sarcoma | Round Cell Sarcoma With EWSR1-non-ETS Fusion | Metastatic High Grade Sarcoma | Sarcoma With BCOR Genetic Alterations | Metastatic Undifferentiated Round Cell Sarcoma | Metastatic Undifferentiated Sarcoma, Not Otherwise Specified
-
NCT02384473CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue Sarcoma
-
NCT01958580TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma
-
NCT05333458RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part Sarcoma | Refractory Alveolar Soft Part Sarcoma
-
NCT07539454Not yet recruitingSkin Kaposi Sarcoma | AIDS-Related Kaposi Sarcoma
-
NCT01106872CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable Sarcoma
-
NCT00004853CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk Sarcoma
-
NCT07432932RecruitingSarcoma | Soft Tissue Sarcoma Adult | Liposarcoma | Angiosarcoma | Soft Tissue Sarcoma of the Limb | Retroperitoneal Sarcoma | Liposarcoma, Dedifferentiated | Leiomyosarcoma (LMS) | Soft Tissue Sarcoma of the Trunk and Extremities | Soft Tissue Sarcoma (STS)
-
NCT04204941TerminatedAdvanced Soft-tissue Sarcoma | Advanced Epithelioid Sarcoma
-
NCT03016819RecruitingLeiomyosarcoma | Synovial Sarcoma | Alveolar Soft Part Sarcoma | Soft-Tissue Sarcoma
Clinical Trials on Proximal Femur Replacement
-
NCT03875027Completed
-
NCT01509859UnknownClosed Comminuted Oblique Intertrochanteric Fracture of Neck of Right Femur | Closed Comminuted Oblique Intertrochanteric Fracture of Neck of Left Femur
-
NCT06928948Enrolling by invitation
-
NCT01128868CompletedReverse Oblique Intertrochanteric Fractures | Reverse Oblique Subtrochanteric Fractures
-
NCT05286905RecruitingPertrochanteric Fracture of Femur, Closed
-
NCT06118736RecruitingCerebral Palsy | Hip Dislocation
-
NCT07410338CompletedUnstable Intertrochanteric Fracture
-
NCT00319085CompletedOsteoarthritis, Hip
-
NCT05804604CompletedFemoral Neck Fractures | Bone Loss | Bone Resorption | Muscle Loss | Muscle Damage | Pertrochanteric Fracture